News

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events.

The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous site monitoring using the ivWatch system was able to detect infiltration and extravasation events earlier than relying on intermittent visual observation alone. Additionally, detection occurred in 100 percent of IV infiltration events with the system, before a clinician could visually detect the event.

The study was extended to a second phase carried out in the IVAS (IV therapy and vascular access) infusion unit between August 2023 and January 2024. In total, 2,254 IVs were monitored using ivWatch’s SmartTouch sensor. Over the 3,507 hours of monitoring, the device issued 122 red Check IV notifications, demonstrating the tech’s ability to identify and prevent injuries in 5.4 percent of infusion activity.

Early identification of IV leakage means patients suffer little, if any, pain or discomfort and no or minimal extravasation injuries.

When applied to the skin near the site of the IV, the ivWatch sensor and monitor carry out over 18,000 checks per hour. If it determines any signs of any leakage of fluid outside of the vein it notifies healthcare workers in real-time, to help reduce the severity of adverse IV events.

The ivWatch technology uses a predictive algorithm and visible and near-infrared light to detect changes in the optical properties of the tissue around an IV site.

Study author Andrew Barton, NHS nurse consultant, IV therapy and vascular access at Frimley Health, and National Infusion and Vascular Access Society (NIVAS) chair, said: “All the patients who returned for multiple infusions during the two-week study requested the use of ivWatch.

“Their feedback was that the use of ivWatch made them feel more safe about receiving their infusion. The infusion nurses also felt reassured by the use of ivWatch, as it gave them peace of mind, too. One staff member said it was like having a second pair of eyes to monitor the infusion site.”

 

Read more here.

Recent News

12/19/2024

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.